AI strengthens grip on low hanging fruit with Exscientia, Dainippon Sumitomo trial start
Exscientia and Dainippon Sumitomo’s trial start for a compound accelerated through preclinical development via AI suggests the technology is starting to deliver on its first promise to drug developers: speeding up the chemistry they already